Physician

Marshall T Schreeder, M.D.

According to 2025 Medicare claims, Marshall Schreeder, M.D. (NPI: 1083693154) practices hematology/oncology in the Huntsville, AL market, with the plurality of this provider's patient population coming from Madison, AL. This provider's primary affiliated billing organization is ONCOLOGY SPECIALTIES, P.C. (NPI: 1669425716; TIN: 630897317) and primary practice location at 35805-2606.

Schreeder's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,092 traditional Medicare patients, billed 303,722 HCPCS/CPT codes, and received $6,250,444 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,041 prescription claims across 396 beneficiaries totaling $6,985,769 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 12 claims. Open Payments data shows 65 records totaling $432,673. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $2,558,496 to $6,985,769. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $40,028 to $3,368.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,247	441,663	$5,198,380
2016	1,500	528,077	$6,385,507
2017	1,266	430,611	$5,432,602
2018	1,168	291,509	$5,677,502
2019	1,159	263,521	$4,886,585
2020	1,052	371,067	$6,176,798
2021	1,102	298,890	$5,929,406
2022	1,181	314,512	$6,755,649
2023	1,130	317,494	$6,543,265
2024	1,092	303,722	$6,250,444

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	362	3,402	$2,558,496
2016	405	3,297	$3,352,903
2017	378	2,988	$3,098,773
2018	402	2,968	$3,078,798
2019	370	2,638	$3,432,848
2020	346	2,791	$4,010,035
2021	357	2,843	$3,685,702
2022	397	2,973	$4,192,795
2023	372	2,768	$4,470,346
2024	396	3,041	$6,985,769

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	44	484	$61,712
2016	22	450	$37,630
2017	11	226	$17,494
2018	N/R	300	$90,006
2019	N/R	197	$86,205
2020	N/R	43	$2,912
2021	N/R	62	$4,580
2022	N/R	37	$2,701
2023	N/R	43	$2,941
2024	N/R	12	$817

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	360	1,002	$90
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	239	869	$12
80053	Blood test, comprehensive group of blood chemicals	881	2,153	$10
36415	Insertion of needle into vein for collection of blood sample	880	2,127	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	890	2,304	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	31	930	$930,739
Revlimid	Lenalidomide	37	1,078	$723,823
Ibrance	Palbociclib	55	1,533	$587,327
Xtandi	Enzalutamide	50	1,500	$564,971
Verzenio	Abemaciclib	42	1,176	$540,890

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$817

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,780	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$430,894	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Marshall T. Schreeder, M.D.?

Tedicare shows public-source Medicare data for Marshall T. Schreeder, M.D. (NPI 1083693154), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Marshall T. Schreeder, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Marshall T. Schreeder, M.D.?

Marshall T. Schreeder, M.D. is linked to ONCOLOGY SPECIALTIES, P.C. (billing NPI 1669425716) in the available physician profile data.

Does Marshall T. Schreeder, M.D. have Open Payments data?

Marshall T. Schreeder, M.D. has 65 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.